After the designated treatments, cells were collected using TRIzol reagent (Invitrogen, Thermo Fisher), and total RNA was extracted from cultured AML cells using Direct-zol RNA kits (Zymo Research, Beijing, China) according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized using a TaKaRa RNA PCR Kit (Takara, Otsu, Japan). Quantitative RT-PCR reactions were carried out on a CFX96 Touch TM Real-Time PCR Detection System (Bio-Rad, CA, USA). Relative mRNA expression was quantified according to the comparative Ct method with normalization to GAPDH. The primers used are displayed in Supplementary Table2.
supplemented with protease inhibitors (ServeBio). The lysates were quantified by the Bradford assay, and equal amounts of lysates were separated by SDS-PAGE and transferred to PVDF membranes (GE Healthcare, NJ, USA). Proteins were detected by immunoblotting using ChemiDoc XRS+ imaging System (Bio-Rad) following incubation with primary antibodies and appropriate secondary antibodies. Images were obtained and analyzed using Image Lab Software (Bio-Rad). The antibodies used are listed in Supplementary Table 3 .
Flow cytometry analysis
Flow cytometry analysis was performed using BD FACSCalibur machine (BD Biosciences) or Beckman Coulter FC500 flow cytometer (Beckman Coulter). To measure the CD34+ cell proportion of human peripheral blood samples, mononuclear cells were collected after isolation and the designated drug treatments. Cells were then washed two times with PBS and stained with anti-CD34 antibody (Biolegend, CA, USA) for 30 minutes at 4℃ . After washing, the samples were subjected to flow cytometry analysis.
To quantify leukemic engraftment in the orthotopic AML xenograft model, the PB and spleen cells were isolated after red cell lysis, labeled with anti-human CD45 antibody (Biolegend) and analyzed by flow cytometry. Data were analyzed using Cytoexpert software (Beckman Coulter) and FlowJo software (version 10.0.7r2; TreeStar, USA).
Generation of FLT3/ITD knock-in Cell Lines
FLT3/ITD knock-in cell lines were generated according to the reported method [1] . To generate short guide RNA (sgRNA) constructs, sequences targeting the 14th exon of FLT3 were loaded at crispr.mit.edu. The BbsI restriction site (CACC) was added to the selected oligos. The oligomers were then annealed and cloned into pSpCas9(BB)-2A-GFP (PX458) under control of the U6 promoter (Addgene # 48138).
To construct the FLT3/ITD donor vector, an up homologous arm located upstream of the FLT3/ITD mutation site and a down homologous arm located downstream of the FLT3/ITD mutation site, approximately 800bp in length on each side, were amplificated by PCR (KOD Fx, Toyobo, Osaka, Japan). Genomic DNA from the primary blast of a FLT3/ITD+ patient was used as a template. The Loxp-BSD-Loxp locus was inserted as a selective marker. Donor segments were then cloned into the vector using pEASY-simple T1 Cloning Kit (TansGene Biotech, Beijing, China) according to the instructions. To avoid unexpected cutting, a synonymous mutation in the donor vector was constructed using the QuikChange® Lightning Site-Directed Mutagenesis Kit (Stratagene, Agilent, CA, USA) following the manufacturer's instructions.
SKM-1 cells (1 × 10 6 cells per well in 1 mL culture medium in a 12-well plate) were co-transfected with 1 µg sgRNA plasmid and 2 µg donor plasmid using Lonza 4D nucleofector (Lonza, Basel, Switzerland) according to a previously reported method [2] . GFP+ cells were sorted by FACS after 2 weeks of BSD drug selection and seeded in a 96-well plate, with a single cell per well. Subsequently, the cells were cultured, expanded and genotyped. For genotyping, PCR reactions were performed using KOD Fx Polymerase (Toyobo) following the manufacturer's instructions. The PCR products were gel-extracted, and the insertion was confirmed by DNA sequencing. FLT3-ITD-Loxp-BSD-Loxp knock-in cells were transfected with 1 µg pBS505 EF1 alpha EGFP Cre (Addgene #11955), and GFP+ cells were sorted by FACS after 72 h and seeded at a single cell per well. After cell expansion, genotyping was performed again, and SKM-1 FLT3-ITD knock-in cells were finally identified.
The primers used for genotyping are listed in Supplementary Table 2 . Conversely, the FLT3/ITD knock-in clones were validated by q-PCR and immunoblotting.
Cell transfection
For Hes1 knockdown, equal amount of non-silencing (NS) or Hes1-targeted (Hes1_1, Hes1_2 and Hes1_3) siRNAs were transfected using Lonza 4D nucleofector (Lonza, Basel, Switzerland) according to the manufacturer's protocol. AC220 was added 24h after transduction. Lentivirus expressing pCDH vector and DNMAML were kindly provided by Hudan Liu (Medical Research Institute, Wuhan University, Wuhan, China) and lentiviral transduction was performed as described before [3] . For transfection, 2x10 5 exponentially growing cells were seeded in 0.5mL culture medium with additional 4μg/mL polybrene (Genechem). Lentivirus were added at an MOI of 25. Three days after transduction, MOLM13 cells were selected in culture medium containing 1ug/mL puromycin for 1 week.
RNA-seq analysis and Gene Set Enrichment Analysis (GSEA)
Principal component analysis (PCA) was performed with R package gmodels The expression of ICN1, ICN2, ICN3 and ICN4 in Molm13 and MV4-11 cells were measured by western blotting following treatment with indicating concentrations of DAPT for 12 h. GAPDH was used as a loading control. Images are representative of three independent experiments. 
Supplemental Figure 2. Effect of AC220 and DAPT on FLT3/WT cells and combinatorial effect of FLT3 TKIs and GSIs on FLT3/ITD+ cells

Supplemental Figure 5. Treatment with sorafenib and DAPT alone or in combination is well tolerated
The mouse weight for each cohort, measured once a week, is shown (n=12). Error bars indicate the average ± SD.
Supplemental Figure 6. Summary of differentially expressed genes (DEGs)
The numbers of differentially expressed genes (DEGs) identified by the gene expression level are presented.
Supplemental Figure 7. Expression of downstream of FLT3
The expression of phospho-STAT5 (pSTAT5), total STAT5, phospho-AKT (pAKT) and total AKT in Molm13 and MV4-11 cells was measured by western blotting following treatment with AC220 (2.5 nM) and/or DAPT (2.5 µM) for 12 h. GAPDH was used as a loading control. Images are representative of three independent experiments.
Supplemental Figure 8. AMG487 had little effect on peripheral blood mononuclear cells from healthy donors
Peripheral blood mononuclear cells obtained from healthy donors(n=4) were treated with 0~25 µM AMG487 for 48 hours and apoptosis was measured by Annexin V binding. Error bars indicate the average ± SD (ns. not significant). 9 . Representative raw plots for apoptosis assay.
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